サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1758868

宇宙医学の世界市場

Space Medicines

出版日
ページ情報
英文 180 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.05円
宇宙医学の世界市場
出版日: 2025年06月30日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

宇宙医学の世界市場は2030年までに16億米ドルに達する見込み

2024年に9億2,290万米ドルと推定される宇宙医学の世界市場は、分析期間2024-2030年にCAGR 10.1％で成長し、2030年には16億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである民間航空宇宙サービスは、CAGR 8.7%を記録し、分析期間終了時には9億3,790万米ドルに達すると予測されます。非民間航空宇宙サービスセグメントの成長率は、分析期間でCAGR 12.1％と推定されます。

米国市場は2億4,260万米ドルと推定、中国はCAGR9.2%で成長予測

米国の宇宙医学市場は、2024年に2億4,260万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 9.2%で推移し、2030年には2億5,430万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.7%と8.3%と予測されています。欧州では、ドイツがCAGR 8.1%で成長すると予測されています。

世界の宇宙医学市場- 主要動向と促進要因のまとめ

宇宙医学が宇宙飛行士の健康、長期滞在ミッション、微小重力駆動型バイオメディカルイノベーションにおいて戦略的関連性を獲得している理由とは？

宇宙医学は、宇宙機関や民間事業者が月、火星、そしてその先への長期ミッションに備える中で、ますます重要になってきています。これらの医薬品は、微小重力による生理的変化、放射線被曝、免疫力の低下、体液の再分配、筋肉や骨の減少など、宇宙環境に特有の健康課題に対処するために特別に設計されたり、再利用されたりしています。人類の宇宙滞在が期間的にも目的地的にも拡大するにつれて、宇宙医学は、ミッションの持続可能性、乗組員の安全性、遠隔軌道の居住地における自律的ヘルスケア提供の重要な実現要因として浮上しています。

同市場は、宇宙環境向けに調整された広範囲の医薬品製剤、送達システム、生物医学的対策を包含します。また、宇宙飛行の研究を通じて開発された診断ツールや治療プロトコールも含まれ、その多くは地球上の病気の治療に応用できる可能性を秘めています。現在、宇宙は生物医学的発見のフロンティアとみなされており、宇宙医学は航空宇宙イノベーションと先進ヘルスケアの交差点に位置しています。

薬剤の安定性、デリバリー技術、宇宙飛行生物学は、宇宙ミッションに対する医療準備をどのように形成しているか？

主な進歩は、真空、温度変動、放射線被曝といった、長期保存中に医薬化合物を劣化させる可能性のある過酷な条件下で、医薬品の有効性を維持することに焦点が当てられています。安定性試験、包装の革新、凍結乾燥は、宇宙での重要な医薬品の保存期間を確保するために最適化されています。

経皮パッチ、口腔内崩壊錠、経鼻スプレーなどの新しいドラッグデリバリーシステムは、投与における微小重力関連の課題を克服するために適応されつつあります。注射や静脈内治療も、宇宙で安全に再構成して使用するための研究が進められています。遠隔医療とAI主導の診断は、リアルタイムの地球上の医療介入なしにミッション中の治療をサポートするために統合されつつあります。

微小重力が細胞機能、遺伝子発現、疾患モデリングに与える影響に関する調査も、特に免疫学、筋骨格系変性、神経前庭疾患、老化促進といった分野における創薬のための独自の経路を明らかにしています。このような洞察により、宇宙で最適化された治療薬の開発が進み、それが地上、特に老人病や慢性疾患の治療に応用される可能性があります。

宇宙医学の需要と革新の原動力となっているミッションや地域プログラムは？

宇宙医学は、主に宇宙飛行研究に従事する国家宇宙機関、学術機関、バイオテクノロジー企業との提携を通じて開発・試験されています。国際宇宙ステーション（ISS）は、医薬品試験や健康対策評価のための最も活発なプラットフォームであり続けています。今後予定されているアルテミスによる月探査と火星探査は、自律的な医療ソリューションと広範な医薬品在庫の必要性を拡大しています。

米国は、NASAのヒューマンリサーチプログラムや、NIHや商業パートナーとの協力により、資金や制度的インフラにおいてリードしています。欧州は、ESAが後援する実験や、生物医学研究における国境を越えたコンソーシアムを通じて貢献しています。日本、中国、インドは、国立研究所や有人宇宙飛行の拡大プログラムを通じて独自の研究課題を推進しており、宇宙医学をミッション・アーキテクチャに組み込むことが増えています。民間部門では、民間宇宙飛行事業者とバイオテクノロジー企業が、宇宙飛行士のケアと地球ベースのヘルスケア・アプリケーションの両方を進歩させるために、無重力研究開発に投資しています。

宇宙医学市場の成長を促進する要因は何ですか？

有人宇宙飛行が長期滞在、商業探査、惑星間飛行という新たな時代に突入するにつれ、宇宙医学市場は拡大しています。病状を自律的に管理し、医薬品の安定性を確保し、長期ミッションにおける乗組員の機能性を維持する必要性が、このニッチでありながら戦略的に重要な領域における需要と技術革新の両方を促進しています。

主な成長促進要因としては、有人宇宙飛行ミッションの増加、宇宙健康調査への投資の増加、医療イノベーションのデュアルユース化、ライフサイエンス研究における国際協力などが挙げられます。自己完結型の医療システム、生物製剤の安定性プロトコール、宇宙に適応した診断法の開発は、宇宙医学を航空宇宙の準備と医学の進歩の両方のフロンティアとしてさらに位置づけています。

人類がより深く、より長い宇宙への旅に備える中で、宇宙医学は宇宙飛行士の健康だけでなく、地球上の個別化された、回復力のある、極限環境ヘルスケアの未来を再定義することができるだろうか？

セグメント

タイプ（民間航空宇宙サービス、非民間航空宇宙サービス）、アプリケーション（腫瘍学、再生医療、神経生物学、微生物学、その他のアプリケーション）、エンドユーザー（商業、政府、軍事、その他のエンドユーザー）

調査対象企業の例

  • Baylor College of Medicine-Center for Space Medicine
  • BioOrbit
  • Blue Origin
  • Delta Biosciences
  • European Space Agency-Space Medicine Office
  • InnovaSpace
  • Institute of Biomedical Problems（IBMP）
  • Japan Aerospace Exploration Agency（JAXA）-Space Medicine
  • Nanotics
  • Orbital Medicine
  • Redwire Space
  • ResearchSat
  • SEAC Space Academy
  • Space Medical Accelerator
  • SpacePharma
  • SpaceTech Analytics
  • SpaceX
  • Translational Research Institute for Space Health（TRISH）
  • Varda Space Industries
  • Voyager Space

AIインテグレーション

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP35804

Global Space Medicines Market to Reach US$1.6 Billion by 2030

The global market for Space Medicines estimated at US$922.9 Million in the year 2024, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 10.1% over the analysis period 2024-2030. Private Aerospace Service, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$937.9 Million by the end of the analysis period. Growth in the Non-Private Aerospace Service segment is estimated at 12.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$242.6 Million While China is Forecast to Grow at 9.2% CAGR

The Space Medicines market in the U.S. is estimated at US$242.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$254.3 Million by the year 2030 trailing a CAGR of 9.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.7% and 8.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.1% CAGR.

Global Space Medicines Market - Key Trends & Drivers Summarized

Why Are Space Medicines Gaining Strategic Relevance in Astronaut Health, Long-Duration Missions, and Microgravity-Driven Biomedical Innovation?

Space medicines are becoming increasingly critical as space agencies and private operators prepare for prolonged missions to the Moon, Mars, and beyond. These medicines are specifically designed or repurposed to address health challenges unique to the space environment, including microgravity-induced physiological changes, radiation exposure, compromised immunity, fluid redistribution, and muscle and bone loss. As human presence in space extends in both duration and destination, space medicines are emerging as a key enabler of mission sustainability, crew safety, and autonomous healthcare delivery in remote orbital habitats.

The market encompasses a broad range of pharmaceutical formulations, delivery systems, and biomedical countermeasures tailored for space conditions. It also includes diagnostic tools and therapeutic protocols developed through spaceflight research, many of which offer potential translational value for treating diseases on Earth. With space now viewed as a frontier for biomedical discovery, space medicine is positioned at the intersection of aerospace innovation and advanced healthcare.

How Are Drug Stability, Delivery Technologies, and Spaceflight Biology Shaping Medical Preparedness for Space Missions?

Key advancements are focused on maintaining drug efficacy in extreme conditions-vacuum, temperature fluctuations, and radiation exposure-all of which can degrade pharmaceutical compounds during long-term storage. Stability testing, packaging innovation, and lyophilization are being optimized to ensure shelf life for critical medications in space.

Novel drug delivery systems such as transdermal patches, orally disintegrating tablets, and intranasal sprays are being adapted to overcome microgravity-related challenges in administration. Injections and intravenous treatments are also under study for space-safe reconstitution and usage. Telemedicine and AI-driven diagnostics are being integrated to support in-mission treatment without real-time Earth-based medical intervention.

Research into microgravity’s impact on cell function, gene expression, and disease modeling is also revealing unique pathways for drug discovery-particularly in the areas of immunology, musculoskeletal degeneration, neurovestibular conditions, and accelerated aging. These insights are advancing development of space-optimized therapeutics that may have dual applications on Earth, especially in geriatric and chronic disease care.

Which Missions and Regional Programs Are Driving Demand and Innovation in Space Medicines?

Space medicines are primarily developed and tested through partnerships with national space agencies, academic institutions, and biotech companies engaged in spaceflight research. The International Space Station (ISS) remains the most active platform for pharmaceutical testing and health countermeasure evaluation. Upcoming Moon missions under Artemis and planned Mars expeditions are expanding the need for autonomous medical solutions and broader pharmaceutical inventories.

The United States leads in funding and institutional infrastructure, driven by NASA’s Human Research Program and collaboration with NIH and commercial partners. Europe contributes through ESA-sponsored experiments and cross-border consortia in biomedical research. Japan, China, and India are advancing their own research agendas via national labs and extended human spaceflight programs, increasingly incorporating space medicine into mission architecture. In the private sector, commercial spaceflight operators and biotech firms are investing in zero-gravity R&D to advance both astronaut care and Earth-based healthcare applications.

What Are the Factors Driving Growth in the Space Medicines Market?

The space medicines market is expanding as human spaceflight enters a new era of long-duration habitation, commercial exploration, and interplanetary ambition. The need to manage medical conditions autonomously, ensure pharmaceutical stability, and maintain crew functionality over extended missions is driving both demand and innovation in this niche yet strategically vital domain.

Key growth drivers include increased human spaceflight missions, rising investment in space health R&D, dual-use medical innovation opportunities, and international collaboration in life sciences research. The development of self-contained medical systems, biologics stability protocols, and space-adapted diagnostics is further positioning space medicine as a frontier of both aerospace readiness and medical advancement.

As humanity prepares for deeper and longer journeys into space, could space medicines redefine not only astronaut health but also the future of personalized, resilient, and extreme-environment healthcare on Earth?

SCOPE OF STUDY:

The report analyzes the Space Medicines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Private Aerospace Service, Non-Private Aerospace Service); Application (Oncology, Regeneration Medicine, Neurobiology, Microbiology, Other Applications); End-User (Commercial, Government, Military, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

  • Baylor College of Medicine - Center for Space Medicine
  • BioOrbit
  • Blue Origin
  • Delta Biosciences
  • European Space Agency - Space Medicine Office
  • InnovaSpace
  • Institute of Biomedical Problems (IBMP)
  • Japan Aerospace Exploration Agency (JAXA) - Space Medicine
  • Nanotics
  • Orbital Medicine
  • Redwire Space
  • ResearchSat
  • SEAC Space Academy
  • Space Medical Accelerator
  • SpacePharma
  • SpaceTech Analytics
  • SpaceX
  • Translational Research Institute for Space Health (TRISH)
  • Varda Space Industries
  • Voyager Space

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Space Medicines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Interest in Long-Duration Space Missions and Human Spaceflight Health Throws the Spotlight on Space Medicines
    • Growth in ISS Research and Private Space Habitats Spurs Demand for Microgravity-Optimized Pharmaceutical Solutions
    • Development of Radiation-Resistant, Thermally Stable, and Extended Shelf-Life Medications Supports In-Space Use
    • Focus on Countermeasures for Bone Loss, Muscle Atrophy, and Immune Suppression Enhances Astronaut Health Protocols
    • Integration of 3D Bioprinting, On-Demand Drug Synthesis, and Portable Compounding Units Enables In-Situ Pharmaceutical Production
    • Rising Inclusion of Spaceflight Stressors in Drug Efficacy Studies Promotes Dual-Use Development
    • Commercialization of Space-Validated Drugs for Earth Applications Expands Technology Transfer Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Space Medicines Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Space Medicines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Space Medicines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Private Aerospace Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Private Aerospace Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Non-Private Aerospace Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Non-Private Aerospace Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Military by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Military by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Commercial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Commercial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Government by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Government by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Regeneration Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Regeneration Medicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Neurobiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Neurobiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Microbiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Microbiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Space Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Space Medicines by Type - Private Aerospace Service and Non-Private Aerospace Service - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Space Medicines by Type - Percentage Breakdown of Value Sales for Private Aerospace Service and Non-Private Aerospace Service for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Space Medicines by End-user - Military, Other End-Users, Commercial and Government - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Space Medicines by End-user - Percentage Breakdown of Value Sales for Military, Other End-Users, Commercial and Government for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Space Medicines by Application - Oncology, Regeneration Medicine, Neurobiology, Microbiology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Space Medicines by Application - Percentage Breakdown of Value Sales for Oncology, Regeneration Medicine, Neurobiology, Microbiology and Other Applications for the Years 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Space Medicines by Type - Private Aerospace Service and Non-Private Aerospace Service - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Space Medicines by Type - Percentage Breakdown of Value Sales for Private Aerospace Service and Non-Private Aerospace Service for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Space Medicines by End-user - Military, Other End-Users, Commercial and Government - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Space Medicines by End-user - Percentage Breakdown of Value Sales for Military, Other End-Users, Commercial and Government for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Space Medicines by Application - Oncology, Regeneration Medicine, Neurobiology, Microbiology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Space Medicines by Application - Percentage Breakdown of Value Sales for Oncology, Regeneration Medicine, Neurobiology, Microbiology and Other Applications for the Years 2025 & 2030
  • JAPAN
    • Space Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Space Medicines by Type - Private Aerospace Service and Non-Private Aerospace Service - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Space Medicines by Type - Percentage Breakdown of Value Sales for Private Aerospace Service and Non-Private Aerospace Service for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Space Medicines by End-user - Military, Other End-Users, Commercial and Government - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for Space Medicines by End-user - Percentage Breakdown of Value Sales for Military, Other End-Users, Commercial and Government for the Years 2025 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Space Medicines by Application - Oncology, Regeneration Medicine, Neurobiology, Microbiology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Space Medicines by Application - Percentage Breakdown of Value Sales for Oncology, Regeneration Medicine, Neurobiology, Microbiology and Other Applications for the Years 2025 & 2030
  • CHINA
    • Space Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Space Medicines by Type - Private Aerospace Service and Non-Private Aerospace Service - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Space Medicines by Type - Percentage Breakdown of Value Sales for Private Aerospace Service and Non-Private Aerospace Service for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for Space Medicines by End-user - Military, Other End-Users, Commercial and Government - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for Space Medicines by End-user - Percentage Breakdown of Value Sales for Military, Other End-Users, Commercial and Government for the Years 2025 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for Space Medicines by Application - Oncology, Regeneration Medicine, Neurobiology, Microbiology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for Space Medicines by Application - Percentage Breakdown of Value Sales for Oncology, Regeneration Medicine, Neurobiology, Microbiology and Other Applications for the Years 2025 & 2030
  • EUROPE
    • Space Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Space Medicines by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Space Medicines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Space Medicines by Type - Private Aerospace Service and Non-Private Aerospace Service - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Space Medicines by Type - Percentage Breakdown of Value Sales for Private Aerospace Service and Non-Private Aerospace Service for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Space Medicines by End-user - Military, Other End-Users, Commercial and Government - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Space Medicines by End-user - Percentage Breakdown of Value Sales for Military, Other End-Users, Commercial and Government for the Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Space Medicines by Application - Oncology, Regeneration Medicine, Neurobiology, Microbiology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Space Medicines by Application - Percentage Breakdown of Value Sales for Oncology, Regeneration Medicine, Neurobiology, Microbiology and Other Applications for the Years 2025 & 2030
  • FRANCE
    • Space Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 58: France Recent Past, Current & Future Analysis for Space Medicines by Type - Private Aerospace Service and Non-Private Aerospace Service - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Space Medicines by Type - Percentage Breakdown of Value Sales for Private Aerospace Service and Non-Private Aerospace Service for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for Space Medicines by End-user - Military, Other End-Users, Commercial and Government - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for Space Medicines by End-user - Percentage Breakdown of Value Sales for Military, Other End-Users, Commercial and Government for the Years 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Space Medicines by Application - Oncology, Regeneration Medicine, Neurobiology, Microbiology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for Space Medicines by Application - Percentage Breakdown of Value Sales for Oncology, Regeneration Medicine, Neurobiology, Microbiology and Other Applications for the Years 2025 & 2030
  • GERMANY
    • Space Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Space Medicines by Type - Private Aerospace Service and Non-Private Aerospace Service - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Space Medicines by Type - Percentage Breakdown of Value Sales for Private Aerospace Service and Non-Private Aerospace Service for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Space Medicines by End-user - Military, Other End-Users, Commercial and Government - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for Space Medicines by End-user - Percentage Breakdown of Value Sales for Military, Other End-Users, Commercial and Government for the Years 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Space Medicines by Application - Oncology, Regeneration Medicine, Neurobiology, Microbiology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for Space Medicines by Application - Percentage Breakdown of Value Sales for Oncology, Regeneration Medicine, Neurobiology, Microbiology and Other Applications for the Years 2025 & 2030
  • ITALY
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Space Medicines by Type - Private Aerospace Service and Non-Private Aerospace Service - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Space Medicines by Type - Percentage Breakdown of Value Sales for Private Aerospace Service and Non-Private Aerospace Service for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Space Medicines by End-user - Military, Other End-Users, Commercial and Government - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for Space Medicines by End-user - Percentage Breakdown of Value Sales for Military, Other End-Users, Commercial and Government for the Years 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Space Medicines by Application - Oncology, Regeneration Medicine, Neurobiology, Microbiology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for Space Medicines by Application - Percentage Breakdown of Value Sales for Oncology, Regeneration Medicine, Neurobiology, Microbiology and Other Applications for the Years 2025 & 2030
  • UNITED KINGDOM
    • Space Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 76: UK Recent Past, Current & Future Analysis for Space Medicines by Type - Private Aerospace Service and Non-Private Aerospace Service - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Space Medicines by Type - Percentage Breakdown of Value Sales for Private Aerospace Service and Non-Private Aerospace Service for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for Space Medicines by End-user - Military, Other End-Users, Commercial and Government - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for Space Medicines by End-user - Percentage Breakdown of Value Sales for Military, Other End-Users, Commercial and Government for the Years 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Space Medicines by Application - Oncology, Regeneration Medicine, Neurobiology, Microbiology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for Space Medicines by Application - Percentage Breakdown of Value Sales for Oncology, Regeneration Medicine, Neurobiology, Microbiology and Other Applications for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Space Medicines by Type - Private Aerospace Service and Non-Private Aerospace Service - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Space Medicines by Type - Percentage Breakdown of Value Sales for Private Aerospace Service and Non-Private Aerospace Service for the Years 2025 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Space Medicines by End-user - Military, Other End-Users, Commercial and Government - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for Space Medicines by End-user - Percentage Breakdown of Value Sales for Military, Other End-Users, Commercial and Government for the Years 2025 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Space Medicines by Application - Oncology, Regeneration Medicine, Neurobiology, Microbiology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 6-Year Perspective for Space Medicines by Application - Percentage Breakdown of Value Sales for Oncology, Regeneration Medicine, Neurobiology, Microbiology and Other Applications for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Space Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Space Medicines by Type - Private Aerospace Service and Non-Private Aerospace Service - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Space Medicines by Type - Percentage Breakdown of Value Sales for Private Aerospace Service and Non-Private Aerospace Service for the Years 2025 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Space Medicines by End-user - Military, Other End-Users, Commercial and Government - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for Space Medicines by End-user - Percentage Breakdown of Value Sales for Military, Other End-Users, Commercial and Government for the Years 2025 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Space Medicines by Application - Oncology, Regeneration Medicine, Neurobiology, Microbiology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 6-Year Perspective for Space Medicines by Application - Percentage Breakdown of Value Sales for Oncology, Regeneration Medicine, Neurobiology, Microbiology and Other Applications for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Space Medicines by Type - Private Aerospace Service and Non-Private Aerospace Service - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Space Medicines by Type - Percentage Breakdown of Value Sales for Private Aerospace Service and Non-Private Aerospace Service for the Years 2025 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Space Medicines by End-user - Military, Other End-Users, Commercial and Government - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for Space Medicines by End-user - Percentage Breakdown of Value Sales for Military, Other End-Users, Commercial and Government for the Years 2025 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Space Medicines by Application - Oncology, Regeneration Medicine, Neurobiology, Microbiology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World 6-Year Perspective for Space Medicines by Application - Percentage Breakdown of Value Sales for Oncology, Regeneration Medicine, Neurobiology, Microbiology and Other Applications for the Years 2025 & 2030

IV. COMPETITION